Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence.
about
Awareness of, experience with, and attitudes toward buprenorphine among opioid users visiting a New York City syringe exchange program.HIV provider endorsement of primary care buprenorphine treatment: a vignette study.Factors affecting willingness to provide buprenorphine treatment.The Physician Clinical Support System-Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment.Patients' Reasons for Choosing Office-based Buprenorphine: Preference for Patient-Centered Care.Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders.Strategies to improve access to and utilization of health care services and adherence to antiretroviral therapy among HIV-infected drug users.Hepatitis infection in the treatment of opioid dependence and abuse.Barriers to use of pharmacotherapy for addiction disorders and how to overcome them.Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients.Office-Based Opioid Treatment with Buprenorphine (OBOT-B): Statewide Implementation of the Massachusetts Collaborative Care Model in Community Health Centers.Pharmacological pain control for human immunodeficiency virus-infected adults with a history of drug dependence.Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physiciansA randomized trial of cognitive behavioral therapy in primary care-based buprenorphine.Nurse practitioner and physician assistant interest in prescribing buprenorphine.Moving HIV pre-exposure prophylaxis into clinical settings: lessons from buprenorphineOffice-based management of opioid dependence with buprenorphine: clinical practices and barriersStructural barriers in the context of opiate substitution treatment in Germany--a survey among physicians in primary careA buprenorphine education and training program for primary care residents: implementation and evaluation.Review: the need for smoking cessation among HIV-positive smokers.Training physicians to treat substance use disordersInquiries about and initiation of buprenorphine treatment in an inner-city clinicIntegration of health services improves multiple healthcare outcomes among HIV-infected people who inject drugs in Ukraine.Barriers to primary care physicians prescribing buprenorphine.Integrating HIV and substance use services: a systematic review.Health systems facilitators and barriers to the integration of HIV and chronic disease services: a systematic review.Steps physicians report taking to reduce diversion of buprenorphine.Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City.Why aren't physicians prescribing more buprenorphine?Medical students' experiences with addicted patients: a web-based survey.Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders.Update in addiction medicine for the generalist.
P2860
Q33576948-0604A0DA-1C41-4E7D-AB86-B0833899A182Q33685481-A1FBB205-C0E9-4853-B5E1-D8900F77E5F6Q33836333-78514369-5FD6-4A81-A020-C48DFABC899EQ34050760-45EF8580-12FF-482D-987F-4D85CA97EBFDQ34408522-D1B7AC9F-A51C-4396-B5E7-D2A4CDF7B5FBQ35061983-838187B6-0023-479E-ADCC-733B061B484BQ35148360-9A51BF54-4439-4089-8630-44CAD13D1F70Q35389163-18B17CA0-3074-4E81-8605-3BBDE8738ED8Q35490468-3B318A80-ECF8-46DA-9FC8-7C30ACA0E0DBQ35691511-4657B86F-09CF-4D7B-93F4-28DCD3250FACQ35733318-C1B7632F-DDEA-4E09-8F8A-648CD6AD7753Q36248583-26A48AB5-EFA7-4BAF-B203-525D081672CDQ36416746-0AA46443-00C0-4411-A027-906838B54E42Q36753425-15982039-4A7F-448C-8F93-09FBB0E3BBC5Q36793941-B96F5E33-5410-411B-9602-C1732E97021FQ36821137-D1907FD9-2364-47A3-AEE6-7FCF96B1AB14Q36841125-BC8CF40D-A2BE-44EF-A9EB-BA3C68BCB18FQ37046304-F82D6A33-6BE9-4914-908C-E015A13C2303Q37237877-782993CE-158F-4858-AC21-8114435BA95AQ37247180-9C6EA41F-DF24-4E63-A9CC-3BD0DF57FDE7Q37273938-5439E71D-F0F3-4CE8-825C-2A88A3D2EBD5Q37353120-53674C69-AC43-4E57-995D-51E325690576Q37397043-3E4D6122-D78D-4C52-9631-9AAE26D4CEF8Q37628725-6C39352A-0684-466E-80B3-B584BE05076FQ38373282-3CE831FC-9123-4B72-BA93-23F653093EBEQ39407502-B028DCD1-4F27-4A5F-8077-6F16842A4FCBQ39429982-362F5677-0C7F-4920-825D-8ADEB60E2562Q41209394-1731315F-1334-4642-A9CB-8A5A3FAA3507Q42024652-9E4E719F-FAED-47A8-A097-66C6B9FA0478Q45788750-B79B7058-F156-43E3-83D5-34455D97361EQ50915503-0D134A63-E124-4B4B-9271-660971AFDC10Q51903799-C5BA1930-890C-4A96-8EF2-F0B8FF2B113A
P2860
Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Barriers and facilitators to p ...... nagement of opioid dependence.
@en
Barriers and facilitators to p ...... nagement of opioid dependence.
@nl
type
label
Barriers and facilitators to p ...... nagement of opioid dependence.
@en
Barriers and facilitators to p ...... nagement of opioid dependence.
@nl
prefLabel
Barriers and facilitators to p ...... nagement of opioid dependence.
@en
Barriers and facilitators to p ...... nagement of opioid dependence.
@nl
P2093
P1476
Barriers and facilitators to p ...... nagement of opioid dependence.
@en
P2093
Barbara J Turner
Kevin Lynch
Yi-Ting Lin
P304
P356
10.1001/ARCHINTE.165.15.1769
P407
P577
2005-08-01T00:00:00Z